ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities.
Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes.
Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 0 |
| Three Month Average Volume | 0 |
| High Low | |
| Fifty-Two Week High | 0.0935 GBX |
| Fifty-Two Week Low | 0.03275 GBX |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 05 Feb 2024 |
| Price and Volume | |
| Current Price | 0.03375 GBX |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -2.24% |
| Thirteen Week Relative Price Change | -1.30% |
| Twenty-Six Week Relative Price Change | -8.29% |
| Fifty-Two Week Relative Price Change | -67.64% |
| Year-to-Date Relative Price Change | -10.83% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | 0.00% |
| Twenty-Six Week Price Change | 0.00% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | -63.51% |
| Year-to-Date Price Change | -3.57% |
| Month-to-Date Price Change | 0.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.08845 GBX |
| Book Value Per Share (Most Recent Quarter) | 0.04237 GBX |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.0852 GBX |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.03911 GBX |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.10278 GBX |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00928 GBX |
| Revenue Per Share (Trailing Twelve Months) | 0.00435 GBX |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 GBX |
| Dividend Per Share (Trailing Twelve Months) | 0 GBX |
| Dividend Per Share (5 Year) | -99999.99 GBX |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.09467 GBX |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.08879 GBX |
| Normalized (Last Fiscal Year) | -0.09467 GBX |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.09467 GBX |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.08879 GBX |
| Including Extraordinary Items (Last Fiscal Year) | -0.09467 GBX |
| Including Extraordinary Items (Trailing Twelve Months) | -0.08879 GBX |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.12511 GBX |
| Cash Per Share (Most Recent Quarter) | 0.08881 GBX |
| Cash Flow Per Share (Last Fiscal Year) | -0.08999 GBX |
| Cash Flow Per Share (Trailing Twelve Months) | -0.0841 GBX |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.09315 GBX |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -659 |
| Cash Flow Revenue (Trailing Twelve Months) | -2,139 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -2,436.55% |
| Pretax Margin (Last Fiscal Year) | -1,256.04% |
| Pretax Margin (5 Year) | -851.83% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,342.45% |
| Operating Margin (Trailing Twelve Months) | -2,466.27% |
| Operating Margin (5 Year) | -875.75% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,020.38% |
| Net Profit Margin (Trailing Twelve Months) | -2,037.35% |
| Net Profit Margin (5 Year) | -714.73% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -39.86% |
| Tangible Book Value (5 Year) | -33.11% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -64.16% |
| Revenue Growth (3 Year) | 65.26% |
| Revenue Change (Trailing Twelve Months) | -68.20% |
| Revenue Per Share Growth | 47.63% |
| Revenue Growth (5 Year) | -55.62% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -1.31% |
| Total Debt (5 Year) | -15.87% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 10.71% |
| EPS Change (Trailing Twelve Months) | 33.78% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -4,730,000 |
| Net Debt (Last Fiscal Year) | -6,732,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 4 |
| Price to Sales (Trailing Twelve Months) | 8 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 5 |
| Long Term Debt to Equity (Most Recent Quarter) | 8 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -7,704,000 |
| Free Cash Flow (Trailing Twelve Months) | -5,326,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 8 |
| Total Debt to Equity (Most Recent Quarter) | 14 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -40.11% |
| Return on Assets (Trailing Twelve Months) | -50.10% |
| Return on Assets (5 Year) | -43.12% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -72.37% |
| Return on Equity (Trailing Twelve Months) | -106.77% |
| Return on Equity (5 Year) | -60.66% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -69.20% |
| Return on Investment (Trailing Twelve Months) | -101.09% |
| Return on Investment (5 Year) | -58.50% |